FRCA Notes


Perioperative Myocardial Infarction



Cardiac troponins

  • The troponin complex regulates contraction and relaxation of the sarcomere:
    • Troponin C: binds calcium
    • Troponin T: anchors the complex to tropomyosin
    • Troponin I: inhibits actin-myosin interaction at rest

  • Cardiac isoforms of TnT and TnI are encoded differently to skeletal muscle isoforms, so they are specific markers of cardiomyocyte damage

  • Troponin may be released by:
    • Necrosis (type 1 or type 2 MI): sarcolemma disrupted; large troponin complexes released
    • Non-necrotic pathways: increased membrane permeability (e.g. stress, inflammation via TNF-α) or intracellular proteolysis; smaller fragments released
    • Current assays cannot distinguish between these
  • High-sensitivity assays detect concentrations 5-10 times lower than older assays and allow the 99th percentile upper reference limit (URL) to be defined

Myocardial injury vs infarction

  • Myocardial injury: troponin above the 99th percentile URL, which is considered acute if there is a rise or fall of ≥20%

  • Acute myocardial infarction (Fourth Universal Definition): acute injury plus clinical evidence of ischaemia, i.e. at least one of:
    • Ischaemic symptoms
    • New ischaemic ECG changes
    • New pathological Q waves
    • Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality (RWMA)
    • Coronary thrombus on angiography or autopsy
  • There can be no infarction without injury, but injury without infarction is common

Types of myocardial infarction

  • Type 1: atherothrombotic i.e. usually plaque rupture leading to coronary occlusion
  • Type 2: oxygen supply-demand mismatch without acute atherothrombosis
  • Type 3: sudden cardiac death with features suggestive of ischaemia

Perioperative definitions

  • All definitions rely on a postoperative troponin rise, but there is no single agreed definition as the cut-offs and timings vary
  • The key distinction is whether an ischaemic mechanism is required:
    • MINS (myocardial injury after non-cardiac surgery): presumed ischaemic, with non-ischaemic causes (e.g. sepsis, PE, rapid AF) excluded
    • PMI (perioperative myocardial injury): any cause, including extracardiac
Definition Criteria
MINS (VISION) TnT >20ng/L within 3 days of surgery, judged to be ischaemic (ischaemic symptoms not required)
MINS (AHA, 2021) Troponin >99th percentile URL with an acute change within 30 days (typically 72 h) and presumed ischaemic mechanism
PMI (Fourth Universal Definition) Troponin >99th percentile URL with ≥20% change of any cause (no features of ischaemia)
PMI (BASEL-PMI) Absolute rise in TnT ≥14ng/L above pre-operative baseline within 7 days (mechanism not considered)
PMI (StEP-COMPAC) Troponin >99th percentile URL without overt ischaemia, regardless of mechanism over any timeframe

  • Symptoms are frequently masked by analgesia and sedation: most perioperative myocardial injury and infarction is clinically silent and is only detected by troponin surveillance

Incidence

  • Myocardial injury is common:
    • 8% of patients aged ≥45 years in the original VISION cohort
    • Approximately 18-20% in pooled analyses using the AHA definition
    • Higher when hs-TnT is used rather than TnI

  • Perioperative MI is less common
    • ~1% of all non-cardiac surgery, rising to over 10% in high-risk groups
    • Most events occur within the first 48-72 h after surgery
    • Up to one third of perioperative MIs are STEMI

Risk factors

  • Patient: older age, male sex, hypertension, coronary artery disease, previous MI, heart failure, chronic kidney disease
  • Surgical: emergency surgery; highest incidence in general surgery and lowest in orthopaedics

Outcomes

  • PMI is associated with increased mortality regardless of mechanism:
    • 30-day mortality approximately 8.5% vs 1.2% without MINS
    • 1-year mortality approximately 21% vs 5%
  • Also associated with reduced disability-free survival at 1 year
  • Outcome varies with aetiology
    • PMI due to acute heart failure or tachyarrhythmia carries the worst prognosis
    • Type 2 PMI is the most common (>70% of cases of PMI) and has the lowest event rate
  • Cardiac MRI has demonstrated myocardial oedema in patients with MINS that correlates with the troponin rise, suggesting it represents genuine myocardial injury rather than a non-specific marker of a frail patient

Ischaemic mechanisms

  • Type 1 (atherothrombosis):
    • Plaque instability promoted by the surgical stress response, inflammation and perioperative hypercoagulability
    • The minority of perioperative MI: coronary thrombus is found in around 13% of postoperative MIs compared with 67% of non-operative MIs

  • Type 2 (supply-demand mismatch):
    • The predominant mechanism, accounting for over 70% of perioperative MI
    • Reduced supply: hypotension, hypoxaemia, anaemia, tachycardia (reduced diastolic time)
    • Increased demand: sympathetic activation from pain, surgical stress and inflammation; tachycardia; hypertension
    • Coronary autoregulation is robust, so type 2 ischaemia requires these compensatory mechanisms to fail

  • Treatments directed at coronary artery disease (aspirin, statins) have not improved outcomes after PMI, supporting a mechanism other than plaque rupture in most patients

Non-ischaemic mechanisms

  • Systemic inflammation:
    • Pre-existing inflammation (e.g. raised neutrophil-lymphocyte ratio) is associated with PMI
    • The surgical stress response causes a pro-inflammatory, catabolic state

  • Mechanical stretch:
    • Increased preload: excessive fluid administration, acute heart failure
    • Increased LV afterload: catecholamine release
    • Increased RV afterload: PE, positive pressure ventilation, lung injury, hypoxia, hypercarbia

  • Autonomic dysfunction:
    • Impaired cardiac vagal function (e.g. delayed heart rate recovery after CPET) is associated with PMI
    • Causes tachycardia, abnormal baroreflex function, increased coronary microvascular tone and inflammation

  • These mechanisms interact, and in reality PMI is likely to be multifactorial

Perioperative management of the patient at risk of myocardial ischaemia


History and examination

  • Symptoms of ischaemia or heart failure; functional capacity (METs)
  • Recent MI or coronary intervention, including stent type and date
  • Valvular heart disease, arrhythmias, decompensated heart failure
  • Current antiplatelet, anticoagulant and cardiovascular medications

Risk assessment

  • The Revised Cardiac Risk Index (Lee) is a simple, validated tool predicting major cardiac complications after elective non-cardiac surgery; one point is given for each factor:
Revised Cardiac Risk Index
High-risk surgery (intraperitoneal, intrathoracic or suprainguinal vascular)
Ischaemic heart disease
History of congestive heart failure
History of cerebrovascular disease
Diabetes requiring insulin
Pre-operative creatinine >177 µmol/L

  • Predicted event rate rises with score: 0.4% (0 points), 0.9% (1), 6.6% (2), 11% (≥3)
  • Limitations: validated for elective surgery only; composite outcome not specific to MI; omits factors such as recent MI, recent stents and valvular disease

Investigations

  • 12-lead ECG; echocardiography where indicated
  • Pre-operative troponin in high-risk patients:
    • Up to a quarter of patients have a raised troponin before surgery
    • A baseline value is needed to distinguish chronic from acute myocardial injury
  • NT-proBNP can help identify high-risk patients for postoperative troponin surveillance
  • Non-invasive stress testing is only recommended if all of the following apply:
    • Surgery is elective
    • Elevated risk of major adverse cardiac events
    • Poor (<4 METs) or unknown functional capacity
    • The result will change management

Recent MI or coronary intervention

  • Reinfarction risk falls with time after MI (approximately 33% within 30 days vs 6% at 3-6 months); delay elective surgery for at least 60 days after MI
  • After PCI, in-stent thrombosis risk is highest early and is associated with high mortality
  • Although dual antiplatelet therapy (DAPT) mitigates this it increases bleeding risk
  • Recommended minimum delay before elective surgery after PCI:
Type of PCI Delay before elective surgery
Balloon angioplasty 14 days
Bare-metal stent 30 days
Drug-eluting stent 6-12 months

  • Urgent surgery within these windows requires MDT discussion (surgeon, cardiologist, anaesthetist) about antiplatelet management; continue aspirin wherever possible
  • Prophylactic revascularisation before surgery offers no benefit in stable coronary artery disease; indications are the same as outside the perioperative setting

Optimisation

  • Beta-blockers:
    • Continue if already established
    • Do not start high-dose beta-blockade immediately before surgery (the POISE trial showed fewer MIs but increased mortality and stroke)

  • Aspirin:
    • POISE-2: aspirin did not reduce death or MI but increased major bleeding
    • Decision to continue should weigh thrombotic against bleeding risk although continue in patients with coronary stents

  • Statins: continue; consider starting at least 2 weeks before vascular surgery
  • ACE inhibitors/ARBs: no difference in PMI whether stopped or continued
  • Clonidine: no benefit
  • General cardiovascular optimisation and lifestyle measures (exercise, smoking and alcohol cessation) are reasonable, although none has been shown to reduce PMI specifically
  • Emergency surgery should not be delayed for cardiac work-up, should proceed with appropriate monitoring and management

Physiological goals

  • The aim is to balance myocardial oxygen supply and demand:
Increase oxygen supply Reduce oxygen demand
Low-normal heart rate (longer diastole) Low-normal heart rate
Normal-high diastolic pressure Avoid hypertension (afterload)
Adequate oxygen content (Hb, SaO2) Avoid high wall tension (excess fluid)
Low coronary vascular resistance Avoid excessive contractility (catecholamine surge)

Monitoring and access

  • ECG:
    • Use precordial leads: V5 alone is the most sensitive single lead (~75%); II + V5 ~80%; II + V4 + V5 ~96%
    • Automated ST-segment analysis can alert to changes
  • Invasive arterial pressure monitoring in high-risk patients
  • TOE: RWMA are an early sign of ischaemia, but routine use is not recommended so reserve for persistent haemodynamic instability
  • Pulmonary artery catheters are not routinely recommended

Anaesthetic technique

  • No technique has been shown to be superior:
    • General vs neuraxial vs regional: no clear difference in outcome
    • Volatile vs TIVA: insufficient evidence to recommend either
    • Nitrous oxide does not increase cardiovascular complications in at-risk patients
  • Focus on avoiding haemodynamic swings at induction, laryngoscopy, surgical stimulation and emergence

Other goals

  • Blood pressure:
    • Intra-operative hypotension (SBP <90 mmHg) is associated with PMI
    • However, a hypotension-avoidance strategy (MAP ≥80 mmHg, withold RAASi) was no better than a hypertension-avoidance strategy (MAP ≥60 mmHg) for major vascular complications (POISE-3)

  • Heart rate: avoid tachycardia through adequate analgesia and depth of anaesthesia; careful titration of beta-blockers if required

  • Oxygen: hyperoxia may worsen infarct size so target normal saturations with the lowest FiO2

  • Transfusion:
    • NICE: restrictive threshold of 70 g/L; 80 g/L in acute coronary syndrome
    • A threshold of 90-100 g/L may be considered in patients with active ischaemia, although evidence is limited

  • Normothermia: mild hypothermia is associated with increased myocardial ischaemia
  • Fluids: avoid excessive administration (increases wall tension and stretch)
  • Avoid selective COX-2 inhibitors as associated with an increased risk of MI

Remote ischaemic preconditioning?

  • Brief cycles of limb ischaemia (typically three cycles of 5 min with a cuff inflated above systolic pressure, each followed by 5 min of reperfusion) to protect distant organs
  • Reduces infarct size in animal models although requires both an intact vagal (neural) pathway and a spleen-mediated humoral response
  • However in human trials no reduction in postoperative myocardial injury was shown (PRINCE, 2025)
  • Not currently recommended in routine practice

Recognising intra-operative ischaemia

  • ECG changes in at least two contiguous leads: ST elevation ≥1 mm, or ST depression ≥0.5 mm and/or T wave inversion
  • New arrhythmia, tachycardia or haemodynamic instability
  • Signs of pulmonary congestion: falling SpO2, reduced compliance, wheeze
  • New RWMA on echocardiography

Managing intra-operative ischaemia

  • Inform the surgeon and consider pausing surgery while stabilising
  • Call for help
  • Confirm: 12-lead ECG, baseline and repeat troponin, echocardiography if unstable

  • Restore supply-demand balance:
    • Treat hypotension, hypoxaemia and anaemia
    • Reduce heart rate: analgesia, depth, beta-blocker if blood pressure allows
    • GTN infusion if blood pressure allows
    • Consider aspirin (via nasogastric tube) following discussion of bleeding risk

  • Consider abandoning surgery: depends on severity of instability, urgency of surgery and how quickly it can be concluded
  • If STEMI or haemodynamic instability arrange urgent cardiology review for consideration of PCI (thrombolysis is usually contraindicated once surgery has begun)
  • An IABP may be considered under cardiology guidance

Troponin surveillance

  • Recommended in high-risk patients by several international bodies, although timings vary:
    • Before and after surgery in the high risk patient (European Guidance)
    • Daily troponin for 3 days + post-operative ECG in high-risk patients (Canadian Guidance)
    • Troponin in the first 2-3 days after surgery (American Guidance)

  • Guidance on what to actually do if there's a raised troponin is limited

Management of myocardial injury

  • There is no proven treatment for PMI
  • Look for and treat underlying cause

  • Other management recommendations vary:
    • Starting aspirin and statin (Canadian Guidance; limited evidence)
    • Starting dabigatran in MINS (MANAGE trial protocol, reduces major vascular complications)

  • Coronary angiography is reserved for very high-risk patients as most events are type 2 and bleeding risk after surgery must be considered
  • A diagnosis of PMI identifies a patient at high cardiovascular risk, which should trigger cardiology follow-up and long-term risk factor management

General care

  • Appropriate level of care with telemetry in high-risk patients
  • Serial ECGs and troponins where suspicion is high
  • Good analgesia, euvolaemia, normothermia and judicious oxygen therapy
  • Restart beta-blockers and other cardiac medications when blood pressure allows
  • Antiplatelet therapyas guided by cardiology if (type 1) MI is confirmed

Principles

  • STEMI is caused by acute thrombotic occlusion of an epicardial coronary artery
  • The benefit of reperfusion is time-dependent: most myocardial necrosis occurs within the first few hours of occlusion, and NICE recommends primary PCI within 120 min
  • An invasive strategy for perioperative MI has been associated with halving of in-hospital mortality
  • Clinicians are reluctant to intervene because of bleeding risk from procedural anticoagulation and DAPT; there is no consensus guideline
  • Management depends on the surgical bleeding risk and the time since surgery; early discussion between surgeon, cardiologist and anaesthetist is essential

Reperfusion options

  • Primary PCI with stent: standard approach; requires DAPT to prevent stent thrombosis (highest risk in first 24-48 h; mortality up to 45%)
  • Balloon angioplasty alone: avoids stent and long-term DAPT but has a risk of acute re-occlusion (~8%)
  • Balloon angioplasty with deferred stenting: temporising option until surgical bleeding risk falls
  • Drug-coated balloons: limited experience
  • Thrombolysis: contraindicated after recent surgery
  • Radial artery access reduces bleeding

Proposed approach

  • A management approach based on bleeding risk and time since surgery has been proposed (not formal guidance):
Bleeding risk 0-24 h 24-48 h 48-72 h
High Bespoke protocol 1 Bespoke protocol 2 Standard (NICE)
Intermediate Bespoke protocol 2 Standard (NICE) Standard (NICE)
Low Standard (NICE) Standard (NICE) Standard (NICE)

  • Bespoke protocol 1: no immediate oral antiplatelets; short-acting IV antiplatelet; balloon angioplasty with deferred PCI; aspirin and ticagrelor once definitive stent placed
  • Bespoke protocol 2: no immediate oral antiplatelets; immediate PCI under short-acting IV antiplatelet cover; follow-on aspirin and ticagrelor
  • Heparin as appropriate during the procedure in both